Lakewood-Amedex Biotherapeutics Inc. (LABT)
Market Closed
15 Oct, 08:00 PM
NASDAQ (CM) NASDAQ (CM) Primary $
0. 61
-0.02
-3.0552%
Pre Market
$
+0.05 +8.5892% 0. 67
1.21M Market Cap
- P/E Ratio
- Div Yield
147,836 Volume
- Eps
$ 0.63
Previous Close Investors:
Want to track LABT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
LABT closed today lower at $0.61, a decrease of -3.0552% from yesterday's close, completing a monthly decrease of -77.1493% or -$2.07. Over the past 12 months, LABT stock lost -92.345%.
LABT is not paying dividends to its shareholders.
Lakewood-Amedex Biotherapeutics Inc. has completed 1 stock splits, with the recent split occurring on Jun 22, 2026.
The company's stock is traded on one exchange.
Lakewood-Amedex Biotherapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| YA Yinka Akinsola Blue Trust Inc. | 11 | $34.54 | $6.93 | -$27.61 | -79.94% |
 Jae Cho Marex Group plc | 48,167 | $151,244 | $29,569.72 | -$121,674.28 | -80.45% |
Lakewood-Amedex Biotherapeutics Inc. (LABT) FAQ
What is the stock price today?
The current price is $0.61.
On which exchange is it traded?
Lakewood-Amedex Biotherapeutics Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is LABT.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 1.21M.
Has Lakewood-Amedex Biotherapeutics Inc. ever had a stock split?
Lakewood-Amedex Biotherapeutics Inc. had 1 splits and the recent split was on Jun 22, 2026.
Lakewood-Amedex Biotherapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Kelvin Cooper CEO | NASDAQ (CM) Exchange | 51255A201 CUSIP |
| US Country | 5 Employees | - Last Dividend | 22 Jun 2026 Last Split | - IPO Date |
Overview
Lakewood-Amedex Biotherapeutics, Inc. is dedicated to the innovation and development of unique antimicrobial therapies aimed at combating various infectious diseases. The company's focus lies in creating effective anti-infective products that target specific viral afflictions, including avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, Lakewood-Amedex operates from its headquarters located in Bradenton, Florida. The company's commitment to advancing healthcare solutions is reflected in its research and development efforts within the biotherapeutics sector.
Products and Services
- Antimicrobial Therapies: Lakewood-Amedex is at the forefront of developing cutting-edge antimicrobial therapies designed to effectively counteract bacterial, viral, and fungal infections. These therapies are backed by extensive research and clinical trials to ensure their efficiency and safety.
- Targeted Anti-Infective Products: The company’s portfolio includes specialized products aimed at specific viral diseases. These products focus on critical infections such as avian influenza, providing innovative treatments to manage and mitigate viral outbreaks.
- Hepatitis B and C Treatments: Lakewood-Amedex is engaged in the development of treatments specifically for hepatitis B and C, targeting one of the most pressing public health challenges globally. Their therapies aim to improve patient outcomes and quality of life.
- Research and Development Services: In addition to product development, Lakewood-Amedex offers R&D services to further enhance its portfolio and discover new therapeutic candidates. These services aim at investigating novel mechanisms of action and optimizing existing formulations.
- Collaboration Opportunities: The company actively seeks partnerships and collaborations with research institutions, pharmaceutical companies, and other stakeholders in the biotherapeutics field. This includes working together on innovative projects aimed at pushing the boundaries of current treatments.
Contact Information
Address: 8031 Cooper Creek Blvd., Unit 103
Phone: 1-941-225-2515
Website: http://www.lakewoodamedex.com
2026 © Marketlog. All Rights Reserved.
